Observes how BCL-2 inhibitor treatments work in routine care for chronic lymphocytic leukemia
Collects real-world records of people with chronic lymphocytic leukemia treated with BCL-2 inhibitor medicines.
Key facts
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Where
- Nanjing, ChinaSee the site
- Trial code
- Registry title
- Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- Oct 2026
- Expected to end
- Oct 2030
- Type of study
- Observational
- Treatments tested
- Not applicable- observational study
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had or are having treatment with a BCL-2 inhibitor. It looks back at routine care records.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed CLL or SLL according to the 2018 iwCLL criteria
- Earlier treatment
- Past or current treatment with a BCL-2 inhibitor-based regimen
Main reasons for not taking part
- Important baseline information is missing
- Treatment exposure data is missing
- Effectiveness or safety cannot be evaluated
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age ≥18 years at the time of enrollment
- Confirmed diagnosis of CLL or SLL according to the 2018 iwCLL criteria
- Prior or ongoing treatment with a BCL-2 inhibitor-based regimen
- Availability of complete key baseline data (e.g., demographic characteristics, disease stage, molecular genetic features, and relevant laboratory parameters) and at least one evaluable post-treatment follow-up record, including effectiveness assessment, safety evaluation, or survival data
Who cannot take part
- Patients with significant missing key baseline information or treatment exposure data, rendering evaluation of effectiveness or safety outcomes not feasible
Where in China
- Jiangsu Province HospitalNanjing, ChinaContact: Huayuan ZHUTaking people
About the trial
What the trial wants to find out
This non-interventional, real-world cohort study aims to evaluate treatment patterns, clinical outcomes, and safety of BCL-2 inhibitor-based regimens in patients with CLL treated in routine clinical practice. Data collected from participating centers will be used to characterize patient demographics, disease characteristics, treatment exposure, effectiveness outcomes, and adverse events, thereby providing real-world evidence to support clinical decision-making and optimize patient management.
Treatments tested
- Not applicable- observational study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Non-Interventional Real-World Cohort Study Evaluating BCL-2 Inhibitor-Based Treatment Regimens for Patients With Chronic Lymphocytic Leukemia (CLL)
- Plain-language title
- Observes how BCL-2 inhibitor treatments work in routine care for chronic lymphocytic leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 October 2026